Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2014

Predicting bone scan positivity after biochemical
recurrence following radical prostatectomy in both
hormone-naive men and patients receiving
androgen-deprivation therapy: results from the
SEARCH database
D. M. Moreira
Northwell Health

M. R. Cooperberg
L. E. Howard
W. J. Aronson
C. J. Kane
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Urology Commons
Recommended Citation
Moreira D, Cooperberg M, Howard L, Aronson W, Kane C, Terris M, Amling C, Kuchibhatla M, Freedland S. Predicting bone scan
positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgendeprivation therapy: results from the SEARCH database. . 2014 Jan 01; 17(1):Article 185 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/185. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

Authors

D. M. Moreira, M. R. Cooperberg, L. E. Howard, W. J. Aronson, C. J. Kane, M. K. Terris, C. L. Amling, M.
Kuchibhatla, and S. J. Freedland

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/185

HHS Public Access
Author manuscript
Author Manuscript

Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 September 10.
Published in final edited form as:
Prostate Cancer Prostatic Dis. 2014 March ; 17(1): 91–96. doi:10.1038/pcan.2013.59.

Predicting bone scan positivity after biochemical recurrence
following radical prostatectomy in both hormone-naive men and
patients receiving androgen-deprivation therapy: results from
the SEARCH database

Author Manuscript

DM Moreira1, MR Cooperberg2, LE Howard3,4, WJ Aronson5,6, CJ Kane7, MK Terris4,8, CL
Amling9, M Kuchibhatla3, and SJ Freedland4,10,11
1The

Arthur Smith Institute for Urology, North Shore Long Island Jewish Health System, New
Hyde Park, NY, USA

2Departments

of Urology, and Epidemiology and Biostatistics, University of California, San
Francisco and Urology Section, Department of Surgery, Veterans Affairs Medical Center, San
Francisco, CA, USA
3Department

of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham,

NC, USA
4Urology

Section, Veterans Affairs Medical Center, Durham, NC, USA

5Urology

Section, Department of Surgery, Veterans Affairs Medical Center, Los Angeles, CA,

Author Manuscript

USA
6Department

of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA,

USA
7Division

of Urology, Department of Surgery, University of California at San Diego Medical
Center, San Diego, CA, USA

8Urology

Section, Division of Surgery, Veterans Affairs Medical Centers and Division of Urologic
Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA, USA

9Division

of Urology, Department of Surgery, Oregon Health and Science University, Portland,

OR, USA
10Division

Author Manuscript

of Urology, Department of Surgery, and the Duke Prostate Center, Duke University
School of Medicine, Durham, NC, USA
11Department

of Pathology, Duke University School of Medicine, Durham, NC, USA

Abstract

Correspondence: Dr DM Moreira, The Arthur Smith Institute for Urology, North Shore Long Island Jewish Health System, 450
Lakeville Road, New Hyde Park, NY 11042, USA. dmoreira@nshs.edu.
Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website (http://www.nature.com/
pcan)
CONFLICT OF INTEREST
The authors declare no conflict of interest.

Moreira et al.

Page 2

Author Manuscript

BACKGROUND—To evaluate the factors associated with positive bone scans after biochemical
recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects
after androgen-deprivation therapy (ADT).
METHODS—Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214
bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional
Cancer Hospital database. Generalized estimating equations and local regression plots were used
to evaluate bone scan positivity by patients’ demographics, pathological features, PSA levels and
kinetics.

Author Manuscript

RESULTS—Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen
in 24 (6%) and 65 (30%) subjects, respectively. In hormone-naive subjects, the higher prescan
PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly
associated with positive scans (P =0.008, P<0.001 and P<0.001, respectively). In subjects after
ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P
=0.011, P<0.001 and P =0.002, respectively). Regression plots showed increased scan positivity
with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects
and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone
scan positivity.
CONCLUSIONS—In both hormone-naive subjects and subjects after ADT, more aggressive and
advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were
associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after
ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and
kinetics may be used as selection criteria for bone scan in these patients.
Keywords
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disease-free survival; metastasis; mortality; prostatectomy; PSA

INTRODUCTION
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Bone scans are routinely used to detect metastasis in patients with prostate cancer; however,
most scans are negative.1 Multiple studies in untreated subjects with prostate cancer suggest
that higher PSA levels, higher Gleason scores and more advanced clinical stages are
associated with higher risk of a positive bone scan.2-12 Patients after biochemical recurrence
(BCR) following radical prostatectomy are at a higher risk of disease progression and the
development of bone metastasis.13 However, presently it is unclear as to when the screening
for bone metastasis should start, how frequent bone scans should be performed and whether
the scans should be done at regular time intervals or triggered by changes in clinical or
biochemical variables. To answer these important questions, one needs to first identify the
factors associated with the development of metastasis and positive bone scans. Previously,
Gleason score, clinical stage and PSA kinetics, such as PSA velocity (PSAV) and PSA
doubling time (PSADT), have all been correlated with the risk that a given scan will show
bone metastasis among hormone-naive men.14-17 Similarly, in men with castration-resistant
nonmetastatic prostate cancer, higher PSA levels and adverse kinetics were independently
associated with faster progression to metastatic disease and death.18,19 These findings
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suggest that the above variables could be used to select subjects for bone scan, potentially
minimizing the number of negative and perhaps unnecessary scans. However, there are
limited tools to stratify patients according to their risk of positive bone scan for metastasis.
Therefore, the primary objective of the present study is to determine the factors associated
with positive bone scans after BCR following radical prostatectomy in both hormone-naive
men and those who had received or were receiving androgen deprivation therapy (ADT)
(henceforth ‘after ADT’) from the Shared Equal Access Regional Cancer Hospital
(SEARCH) database. The secondary objective of the study is to use PSA levels and PSADT
to stratify bone scans according to the risk of positivity.

MATERIALS AND METHODS
Study population

Author Manuscript
Author Manuscript
Author Manuscript

After obtaining institutional review board approval from each institution, data from prostate
cancer patients with BCR following radical prostatectomy undergoing bone scan for
suspicion of metastatic disease between 1995 and 2012 at six Veteran Affairs Medical
Centers (West Los Angeles, Palo Alto and San Diego, CA; Augusta, GA; Durham and
Asheville, NC) were included in the study database.20 The database included information on
the patients’ age at the time of bone scan, race, height, weight, preoperative PSA levels,
surgical specimen pathology (specimen weight, tumor grade, stage and surgical margin
status), follow-up PSA, bone scans and secondary treatments after surgery. Patients treated
with preoperative ADT or radiotherapy were excluded from the study. Bone scans following
a positive bone scan were excluded. A total of 1 303 bone scans (from 665 subjects) after
BCR (defined as a single PSA above 0.2 ng ml−1, 2 PSA at 0.2 ng ml−1 or secondary
treatment for an elevated PSA level) following radical prostatectomy were identified.21 Of
these, 97 (7%) scans were done after a positive scan and were excluded from the study. A
total of 694 (58%) scans had complete data including PSA levels and PSA kinetics at the
time of the scan. Of these, 100 scans (8%) with negative PSAV were excluded given that
these likely had PSAV determined during the start of ADT when PSA level was declining.
Such PSA kinetics do not reflect the long-term PSA trends, they only demonstrate the acute
effect of ADT on PSA levels. This resulted in a final study sample of 594 (49%) bone scans
(from 401 subjects). Of these, 380 (64%) bone scans were done among 301 men who had
not received ADT and 214 (36%) scans were done in 137 subjects after ADT. Bone scans
done within 30 days after the start of ADT were considered before ADT. Supplementary
Figures S1 and S2 show the number of scans per patient. Secondary treatments for
recurrence were at the discretion of the patient and the treating physician. The number and
interval of bone scans were also at the discretion of the patient and the treating physician.
Bone scans were read by nuclear medicine radiologists. Radiologists were not blinded to
patients’ demographics, laboratory, radiologic or pathologic results. Bone scan reports were
coded as positive or negative based on the radiology report (equivocal scans were
considered negative unless confirmed positive by a secondary imaging modality).
Statistical analysis
PSADT was calculated using the natural log of two (0.693) divided by the slope of the linear
regression of the natural log of PSA levels over time (in months). Subjects with calculated
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PSADT >120 were assigned 120 months for the ease of analysis. PSAV was calculated as
the slope of the linear regression of PSA levels over time in years. Subjects were required to
have at least two values separated by at least 3 months to have PSA kinetics calculated. All
available PSA levels before the bone scan and before ADT but after BCR (that is, >0.2 ng
ml−1) were used to calculate preADT PSA kinetics. All available PSA levels before bone
scan but after ADT were used to calculate postADT PSA kinetics. Subjects with three or
more PSA values over the 3 months or more had PSA kinetics calculated. Statistical analysis
was done by stratifying bone scans based on ADT status, that is, whether they were done in
hormone-naive subjects or in subjects after ADT. Given the repeated-measures nature of our
data, generalized estimating equations were used to compare patients’ demographics,
pathological features, PSA levels and kinetics between negative and positive scans, grouping
by patient (primary objective). PSA levels were then arbitrarily broken down into four
groups: 0.0–4.9, 5.0–9.9, 10.0–19.9 and ≥20.0 ng ml−1. Similarly, PSADT was divided into
three groups: ≥9, 3–8.9 and <3 months (based on previous studies correlating these values
with mortality).22 Bar plots were used to demonstrate the relative prevalence of positive
bone scans by PSA and PSADT groups stratified by ADT status and linear trends were
evaluated with generalized estimating equations. We also used local regression (LOESS)
plots to graphically represent the relationship between bone scan positivity and PSA level
and PSADT as continuous variables stratified by ADT status. Finally, a table of point
estimates and 95% confidence intervals for probability of bone scan positivity by PSA and
PSADT groups stratified by ADT status were estimated from the generalized estimation
equations (secondary objective). All statistical analyses were two-tailed and performed using
Stata 11.2 (StataCorp, College Station, TX, USA). A P<0.05 was considered statistically
significant.

Author Manuscript
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RESULTS

Author Manuscript

Of the 308 bone scans done among hormone-naive subjects, 24 (6%) scans were positive
and 356 (94%) were negative for metastasis (Table 1). The median time from surgery to
recurrence was 5 years. A higher pathological Gleason score was observed among positive
scans: 50% of the positive scans were done in subjects with Gleason scores of 4 + 3 or 8–10
and only 34% of the negative scans were done in subjects with high-grade Gleason scores.
This difference, however, was not statistically significant. Similarly, the prevalence of
positive surgical margins, extracapsular extension and seminal vesicle invasion were all
higher among positive bone scans but the differences were not statistically significant. The
median PSAV values among subjects with positive scans (8.8 ng ml−1 per year) was
statistically significantly higher than those with negative scans (0.6 ng ml−1 per year,
P<0.001). The median prescan PSA values were significantly higher for positive bone scans
(2.9 ng ml−1) compared with negative bone scans (1.1 ng ml−1, P =0.008). The median
prescan PSADT of subjects with positive bone scans was significantly shorter than those
with negative scans (4.7 versus 13.0 months, respectively, P<0.001).
Of the 214 bone scans done among subjects after ADT, 65 (30%) scans were positive and
149 (70%) were negative for metastasis (Table 2). The median time from surgery to
recurrence and that from surgery to ADT were 6.4 and 11.3 years, respectively. Similar to
bone scans done among hormone-naive subjects, the median prescan PSA and PSAV values
Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 September 10.
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were considerably higher (31.0 ng ml−1 and 13.4 ng ml−1 per year, respectively) for positive
bone scans compared with negative bone scans (2.1 ng ml−1 and 1.7 ng ml−1 per year,
correspondingly; all P<0.05). The median prescan PSADT for positive bone scans was 3.7
months compared with 7.2 months for negative scans (P =0.002).
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In both hormone-naive subjects and those after ADT, there was an increase in bone scan
positivity with an increase in prescan PSA levels (all P for trend <0.001, Figure 1a).
Similarly, among both groups there was an increase in bone scan positivity with shortening
prescan PSADT (all P for trend <0.001, Figure 1b). Figure 2a shows the relationship
between prescan PSA levels and bone scan positivity. For a given prescan PSA level, the
bone scan positivity risk was considerably higher in subjects after ADT compared with
hormone-naive subjects. For example, in the postADT setting, a PSA of 25 ng ml−1
corresponded to nearly 40% risk of a positive scan, whereas in the hormone-naive setting,
the PSA level needed to be >50 ng ml−1 before a 40% risk of a positive scan was achieved.
Figure 2b shows the relationship between prescan PSADT and bone scan positivity. For a
given PSADT, the bone scan positivity was likewise noticeably higher among subjects after
ADT compared with hormone-naive subjects.
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Given prescan PSA levels and PSA kinetics were the two strongest predictors of bone scan
positivity, we developed a table that estimates bone scan positivity by prescan PSA levels
and prescan PSADT stratified by ADT status (Table 3). For example, among bone scans
done in hormone-naive subjects with PSADT ≥9 months, the estimated bone scan positivity
was 5% or less compared with 10% or greater for those with PSADT <9 months. In scans
done among subjects after ADT, for the same PSA level and PSADT, the scan positivity was
higher compared with scans done in hormone-naive subjects with no group (even PSA <5ng
ml−1 and PSADT >9 months) having an estimated bone scan positivity risk <10%.

DISCUSSION

Author Manuscript

With the advances in chemo- and immunotherapies for metastatic prostate cancer in recent
years, early detection of metastasis has become more and more important. However, it is not
clear when and how patients should be screened for metastasis. Bone scans are routinely
used to detect metastasis in patients with prostate cancer; however, a significant number of
these scans are negative. To better select patients for bone scans, we evaluated the predictors
of positive bone scans. We found that the factors associated with more aggressive and
advanced disease such as higher PSA levels, higher PSAV and shorter PSADT were
associated with positive bone scans in both hormone-naive subjects and those after ADT. In
other words, in both groups there was a statistically significant increase in bone scan
positivity with an increase in prescan PSA levels and shortening PSADT. Importantly, for
the same prescan PSA level and PSADT, the bone scan positivity was much higher among
subjects after ADT. These results suggest that more aggressive and/or advanced diseases are
associated with higher risk of a positive bone scan. Furthermore, they suggest that the
factors associated with aggressive and advanced disease such as high PSA levels and short
PSADT may be used to stratify patients based on risk of a positive bone scan. Indeed, we
created a table combining PSA levels and PSADT to predict the risk of a positive bone scan
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that may help clinicians estimate the risk of a positive bone scan to help guide imaging for
men with BCR after surgery.
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Only a few studies evaluated the use of PSA levels and PSA kinetics to predict metastatic
disease in patients with recurrent disease after primary treatment for prostate cancer (radical
prostatectomy and/or radiotherapy). Slovin et al14 found baseline PSA levels and PSADT
were independently predictive of metastatic progression. However, in their study, they did
not evaluate different PSA and PSADT cut points. Also, they did not include patients
receiving ADT. Similarly, Okotie et al,15 studying hormone-naive patients after BCR
following radical prostatectomy, found the risk of metastasis to have increased with PSADT
shorter than 6 months (especially those with PSA levels >10 ng ml−1). Likewise, Dotan et
al,16 also studying hormone-naive patients, found PSA levels and kinetics to be associated
with the risk of a positive bone scan. They used pathological and biochemical variables to
create a nomogram to predict bone scan positivity. In our study of patients after BCR
following radical prostatectomy, we also observed an association between PSA levels and
PSA kinetics with bone metastasis. Furthermore, we evaluated the prevalence of positive
bone scans across multiple PSA and PSA-kinetic groups. Our results suggest that, for
hormone-naive subjects, screening should start once PSADT is shorter than 9 months, given
the risk of a positive bone scan in subjects with PSADT ≥9 months is 2% or less. Even
among men with high PSA values, the estimated risk of a positive bone scan in hormonenaive men with a long PSADT was very low. For subjects after ADT, we were unable to
identify a subgroup where the risk of a positive scan was that low. Even the lowest risk
groups (that is, low PSA levels and long PSADTs) had a risk of a positive scan of 10% or
greater. This suggests that bone scan for patients after ADT should begin early—even before
the PSA level reaches 5 ng ml−1 regardless of PSADT. Assuming the initial bone scan is
negative, PSA levels and PSADT can be used to estimate the risk of a positive bone scan in
these patients and help guide the timing of subsequent imaging.
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The main limitation of the present study is its retrospective nature. Consequently, we were
not able to decide when and how bone scans were performed. It is plausible that patients
with more advanced and aggressive disease at baseline had more and earlier bone scans in
comparison to those with less advanced and aggressive disease for whom the bone scan may
have been deferred to a later point of time. If this hypothesis is true, some patients with
worse disease were more likely to be diagnosed with metastasis, whereas a number of
patients with more favorable disease may have been excluded from the study, given they
have never had a single bone scan. Similarly, we had no control over when and how patients
were treated with ADT. Moreover, nearly 40% of our sample had missing PSA kinetics and
were excluded from the study. In addition, PSA measurements were not systematic and were
at the discretion of the treating physician, which also adds noise and unwanted variability to
the study. Also, repeated measures were present in our data (that is a single patient had more
than one bone scan), which increase the complexity of our statistical analysis. In addition,
the small number of events—especially in the hormone-naive population, resulted in large
confidence intervals in our ability to estimate bone scan positivity as a function of PSA and
PSADT. Finally, although bone scans are very sensitive to detect metastasis, false positive
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and negative do occur, but we were unable to identify them given the confirmatory imaging
was not available for all patients in our sample.23
In conclusion, among prostate cancer patients with BCR following radical prostatectomy,
for a given PSA level and PSADT, subjects after ADT had a higher risk of bone scan
positivity. More aggressive and advanced disease identified by higher PSA levels, higher
PSAV and shorter PSADT were associated with higher risk of a positive bone scan.
Therefore, PSA level and PSA kinetics may be used as selection criteria for performing bone
scans in both hormone-naive subjects and subjects after ADT.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Bone scan positivity by prescan PSA (a) and PSADT (b) groups. ADT, androgendeprivation therapy; PSADT, PSA doubling time.
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Figure 2.

Bone scan positivity by prescan PSA (a) and PSADT (b) levels. ADT, Androgen
deprivation therapy; PSADT, PSA doubling time.
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Bone scans done after BCR and before ADT
Variables

Positive bone scan

Negative bone scan

OR (95% CI)a

Pb

24 (6)

356 (94)

—

—

69 (65, 77)

68 (64, 74)

1.03 (0.97–1.08)

0.352

Bone scans, Total N (%)
Age (years), median (Q1, Q3)
Race, N (%)

0.628

White

16 (67)

231 (65)

ref.

Black

6 (25)

109 (31)

0.79 (0.30–2.07)

Other

2 (8)

16 (4)

1.81 (0.38–8.49)

2004 (1998, 2008)

2004 (1999, 2007)

0.98 (0.90–1.07)

0.704

11.9 (7.2, 18.2)

9.2 (5.7, 16.7)

1.00 (0.996–1.003)

0.808

2–6

3 (17)

76 (25)

ref.

3+4

6 (33)

127 (41)

1.20 (0.29–4.93)

4+3, 8–10

9 (50)

107 (34)

2.13 (0.56–8.13)

Positive surgical margins, N (%)

11 (61)

162 (56)

1.23 (0.46–3.24)

0.681

Extracapsular extension, N (%)

11 (58)

104 (36)

2.46 (0.97–6.23)

0.057

Seminal vesicle invasion, N (%)

5 (26)

64 (20)

1.45 (0.51–4.15)

0.486

Year of scan (years), median (Q1, Q3)
Preoperative PSA (ng

ml−1),

median (Q1, Q3)

Pathological Gleason score, N (%)

0.411
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Lymph nodes, N (%)

0.932

Positive

1 (4)

11 (3)

1.45 (0.18–11.91)

Negative

16 (73)

257 (73)

ref.

Unknown

Author Manuscript

5 (23)

85 (24)

0.94 (0.34–2.65)

Prescan PSA (ng ml−1), median (Q1, Q3)

2.9 (0.6, 12.3)

1.1 (0.4, 3.4)

1.03 (1.01–1.05)

0.008

Prescan PSADT (months), median (Q1, Q3)

4.7 (3.1, 7.8)

13.0 (7.9, 23.9)

0.25 (0.14–0.47)c

<0.001

Prescan PSAV (ng ml−1 per year), median (Q1, Q3)

8.8 (1.7, 42.0)

0.6 (0.2, 1.5)

1.06 (1.03–1.09)

<0.001

Time from BCR to scan (months), median (Q1, Q3)

31.5 (21.7, 62.0)

30.1 (13.3, 59.8)

1.00 (0.99–1.01)

0.848

Abbreviations: ADT, androgen-deprivation therapy; BCR, biochemical recurrence; CI, confidence interval; OR, odds ratio; PSADT, PSA doubling
time; PSAV, PSA velocity; Q1, 25th percentile; Q3, 75th percentile; ref., reference group.
Missing values indicate that the model did not converge.
a

Odds ratios are estimated using GEE logistic regression.

b

P-values are for the significance of the covariate in predicting risk of a bone scan being positive, across all patients.

c

log-transformed PSADT was used in this analysis.
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Table 2

Author Manuscript

Bone scans done after BCR and after ADT
Variables

Positive bone scan

Negative bone scan

OR (95% CI)a

Pb

65 (30)

149 (70)

—

—

71 (65, 76)

70 (64, 77)

1.01 (0.98–1.05)

0.502

Bone scans, N (%)
Age (years), median (Q1, Q3)
Race, N (%)

0.550

White

47 (73)

98 (66)

ref.

Black

15 (24)

45 (30)

0.70 (0.36–1.36)

Other

2 (3)

6 (4)

0.71 (0.14–3.63)

2006 (2001, 2008)

2006 (2003, 2008)

0.94 (0.88–1.01)

0.088

10.5 (6.4, 17.9)

9.4 (6.4, 15.2)

1.00 (0.9998–1.0002)

0.391

2–6

9 (15)

9 (7)

ref.

3+4

14 (23)

45 (33)

0.30 (0.10–0.90)

4+3, 8–10

38 (62)

80 (60)

0.44 (0.16–1.18)

Positive surgical margins, N (%)

33 (57)

75 (60)

0.86 (0.46–1.60)

0.631

Extracapsular extension, N (%)

33 (58)

60 (49)

1.42 (0.76–2.66)

0.272

Seminal vesicle invasion, N (%)

29 (48)

57 (41)

1.31 (0.73–2.35)

0.361

Year of scan (years), median (Q1, Q3)
Preoperative PSA (ng

ml−1),

median (Q1, Q3)

Pathological Gleason score, N (%)

0.097

Author Manuscript

Lymph nodes, N (%)

0.941

Positive

6 (9)

16 (11)

0.84 (0.31–2.26)

Negative

51 (80)

116 (78)

ref.

Unknown

7 (11)

17 (11)

0.95 (0.37–2.41)

31.0 (5.6, 151.3)

2.1 (0.4, 13.2)

1.002 (1.0006–1.004)

0.011

3.7 (2.9, 6.9)

7.2 (4.1, 13.9)

0.58 (0.41–0.82)c

0.002

Prescan PSAV (ng ml−1 per year), median (Q1, Q3)

13.4 (4.3, 48.9)

1.7 (0.44, 6.0)

1.011 (1.005–1.016)

<0.001

Time from BCR to scan (months), median (Q1, Q3)

55.6 (33.8, 107.6)

71.8 (39.4, 105.5)

0.998 (0.991–1.004)

0.491

Prescan PSA (ng ml−1), median (Q1, Q3)
Prescan PSADT (months), median (Q1, Q3)

Author Manuscript

Abbreviations: ADT, androgen deprivation therapy; BCR, biochemical recurrence; CI, confidence interval; OR, odds ratio; PSADT, PSA doubling
time; PSAV, PSA velocity; Q1, 25th percentile; Q3, 75th percentile; ref., reference group.
Missing values indicate that the model did not converge.
a

Odds ratios are estimated using GEE logistic regression.

b

P-values are for the significance of the covariate in predicting risk of a bone scan being positive, across all patients.

c

log-transformed PSADT was used in this analysis.
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11 (9–14)
24 (11–43)

3–8.9

<3

22 (5–60)

10 (3–27)

1 (0–6)

5–9.9

53 (26–79)

31 (16–53)

5 (2–15)

10–19.9

PSA (ng

ml−1)

Before ADT

44 (22–68)

24 (14–37)

3 (1–10)

≥20

26 (20–33)

19 (16–22)

10 (8–13)

0–4.9

Abbreviations: ADT, androgen deprivation therapy; PSADT, PSA doubling time.

1 (1–2)

0–4.9

≥9

PSADT (months)

40 (22–61)

30 (17–48)

17 (8–32)

5–9.9

57 (45–69)

47 (36–58)

30 (21–40)

10–19.9

PSA (ng ml−1)

After ADT

67 (61–73)

57 (52–62)

39 (32–47)

≥20

Author Manuscript

Percent risk of positive scan by PSA and PSADT groups stratified by ADT status

Author Manuscript
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